logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Expected and Unexpected Reasons for Pfizer and Intercept Stocks' Rallies

PFIZER Pfizer (PF)  announced that its oral drug tofacitinib in doses of 5 mg and 10 mg twice daily  met Phase 3 endpoints on psoriatic arthritis. The trial was conducted on adult patients with active psoriatic arthritis (PsA). The recruited...

Read More

April 5, 2016

0

TapImmune and Loxo Oncology Have Interesting News

The AACR 2016 meeting presentations differed substantially from previous meetings. The  2016 meeting has brought near certainty that, indeed, defeating cancer is a reachable objective. The road is lengthy, but the speed in analyzing the data and acting upon them...

Read More

April 25, 2016

0

Agenus First Immune Check Protein Inhibitor in Clinical Trial. See Also: IMGN and EXEL

Biotech N E W S   AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has been dosed in Agenus (AGEN) Phase 1 clinical trial of its checkpoint inhibitor product AGEN1884. The open-label, multicenter trial in patients...

Read More

April 27, 2016

0

Who Will End Up Acquiring Medivation? Abbott Acquires St Jude. See Also: Alnylam

Medivation is a Target for Acquisition The Question is: Who Will Acquire Medivation? Sanofi  has made a bid to acquire Medivation for $9.3 billion (£6.37B ). Sanofi is expected to pay $52.50 per share in cash for Medivation. Why Medivation? Sanofi's chief executive...

Read More

April 28, 2016

0

CRISPR Therapeutics' Worthwhile Deal

CRISPR Therapeutics   (CRSP) and Massachusetts General Hospital Cancer Center (MGHCC) have entered into a two-year research collaboration and license option agreement to develop Novel T cell therapies for cancer. As part of the collaboration, CRISPR/Cas9 gene editing technology will be utilized...

Read More

August 28, 2017

0

About Innoviva Inhalers

Earlier this month, on Aug. 24, 2017, Propeller Health announced the expansion of its 2015 collaboration with GlaxoSmithKline (GSK) , enabling both companies to prepare for and undertake commercial activities using the Propeller clip-on sensor and software platform for use...

Read More

August 29, 2017

0

Why Investors Caused a Selloff of Alnylam’s Stock

Alnylam (ALN)  is probably experiencing a stock selloff following the announcement of successful results from  Pfizer’s (PFE)  drug tafamidis.    Indeed, results from Phase 3 ATT-ACT clinical trial demonstrate that tafamidis succeeded in treating Transthyretin Cardiomyopathy,  a  subtype of TTR amyloidosis...

Read More

April 2, 2018

0

Yes, the Biotech Evolution is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis

THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If  They Sell the Best of the Best  Biotechnology Firms Only Because the Market Is Weird   Even if one is scared and feels he should sell shares, he must be wise...

Read More

April 5, 2018

0

Novartis to acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?

NOVARTIS TO ACQUIRE AVEXIS A few months ago,  Novartis (NVS)  CEO agreed to cash out of the company’s consumer health joint venture with   GlaxoSmithKline (GSK) , which brought in cash intended to further improve and expand Novartis’ pipeline. Here...

Read More

April 10, 2018

0

Illumina’s Contribution to Practicing Precision Medicine

When we reiterated that  Illumina (ILMN)  is the engine of the biotechnology evolution we meant it. We have to add, though, that the evolution made possible by Illumina’s sequencers and next-generation sequencing (NGS) engine is tremendously improving research and medical...

Read More

April 11, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 31
  • 32
  • 33
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy